PPI-101 / Peak Perform Innova Biotechnology - LARVOL DELTA

Favorable DMPK properties enable development of a novel arylsulfonamide RBM39 molecular glue degrader, PPI-101, for the treatment of neuroblastoma (AACR 2026) - "This study defines, for the first time, the in vivo PK/PD relationships governing RBM39 degradation and demonstrates that favorable distribution properties can markedly enhance therapeutic index. PPI-101 emerges as a potent and safer RBM39 degrader candidate for neuroblastoma therapy, warranting GLP toxicology and IND-enabling development."

Neuroblastoma • Oncology • Solid Tumor • IL17RB • RBM39